The independent source for health policy research, polling, and news.
201-220 of 1,325 results
High school students in Colorado are pushing for a change they say is necessary to combat fentanyl poisoning: ensuring students can't get in trouble for carrying the overdose reversal drug naloxone wherever they go, including at school.
Did the price of insulin go down? It’s not quite that simple. On this episode of “An Arm and a Leg,” producer Emily Pisacreta explores recent changes to the cost of the diabetes medication.
A restructuring of the Medicare drug benefit has wiped out big drug bills for people who need expensive medicines. But the legal battle over drug negotiations means uncertainty over long-term savings.
A federal district court judge dismissed a lawsuit attempting to invalidate the Biden administration’s Medicare prescription-drug price negotiation program. But the suit turned on a technicality, and several more court challenges are in the pipeline. Meanwhile, health policy pops up in Super Bowl ads, as Congress approaches yet another funding deadline. Alice Miranda Ollstein of Politico, Lauren Weber of The Washington Post, and Rachel Cohrs of Stat join KFF Health News’ Julie Rovner to discuss these issues and more. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.
KFF Health News and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
As science skepticism pervades politics, the Supreme Court will soon consider two cases that seek to define the power of “experts.” Meanwhile, abortion opponents are laying out plans for how Donald Trump, if reelected as president, could effectively curtail abortion even in states where it remains legal. Sandhya Raman of CQ Roll Call, Joanne Kenen of Johns Hopkins University and Politico Magazine, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News’ Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Samantha Liss, who reported and wrote the latest KFF Health News-NPR “Bill of the Month” feature about a husband and wife who got billed for preventive care that should have been fully covered.
Injectable penicillin is the go-to treatment for syphilis and the only treatment considered safe for pregnant people with the disease. But as rates of syphilis increase across the U.S., a shortage of the injectable has prompted some public health agencies to ration it.
It’s a big job clearing out so-called “patent thickets” drugmakers create to keep their products’ prices high. But the Federal Trade Commission is giving it a shot.
Ketamine, approved by the FDA as an anesthetic in 1970, is emerging as a major alternative mental health treatment, and there are now more than 500 ketamine clinics around the country. But with little regulation and widely varying treatment protocols, it’s a medical "wild West."
As national prescription drug distributors and pharmacies restricted the flow of oxycodone and other painkillers in response to the growing opioid crisis, Florida’s most popular grocery store ramped up its sales and distribution of the highly addictive drugs, according to a Tampa Bay Times analysis of federal data.
New Hampshire voters have spoken, and it seems increasingly clear that this November’s election will pit President Joe Biden against former President Donald Trump. Both appear to be making health a key part of their campaigns, with Trump vowing (again) to repeal the Affordable Care Act, and Biden stressing his support for contraception and abortion rights. Meanwhile, both candidates will try to highlight efforts to rein in prescription drug prices. Alice Miranda Ollstein of Politico, Anna Edney of Bloomberg News, and Jessie Hellmann of CQ Roll Call join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Sarah Somers of the National Health Law Program about the potential consequences for the health care system if the Supreme Court overturns a key precedent attempting to balance executive vs. judicial power.
When bankers and investors flocked to San Francisco for the largest gathering of health care industry investors, the buzz was all about artificial intelligence, the next hit weight-loss drug, and new opportunities to make money through nonprofit hospitals.
KFF Health News senior correspondent Aneri Pattani made the rounds on national and local media in the last two weeks to discuss the opioid settlement funds flowing to state and local governments and her reporting on the topic. Here’s a collection of her appearances.
Alex Azar advanced Canadian drug importation as Donald Trump’s secretary of Health and Human Services. Now he chairs the board of a company managing Florida’s importation program.
KFF Health News and California Healthline staffers made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
It's been more than a year since the FDA declared a national shortage of Adderall, and it’s affecting more than just patients with ADHD. Those with narcolepsy, a much rarer condition, are often treated with the same medication. Without it, they're often unable to drive or function as usual.
2023 was another busy year in health care. As the covid-19 pandemic waned, policymakers looked anew at long-standing obstacles to obtaining and paying for care in the nation’s health care system. Meanwhile, abortion has continued to be an issue in much of the nation, as states respond to the Supreme Court’s 2022 decision overturning the constitutional right to the procedure. This week, Rachel Cohrs of Stat, Sandhya Raman of CQ Roll Call, and Joanne Kenen of Johns Hopkins University and Politico Magazine join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and wrap up the year in health. Also this week, Rovner interviews KFF Health News’ Jordan Rau about his joint KFF Health News-New York Times series “Dying Broke.”
In the past year, opioid settlement money has gone from an emerging funding stream for which people had lofty but uncertain aspirations to a coveted pot of billions being invested in remediation efforts. Here are some important and evolving factors to watch going forward.
© 2026 KFF